Navigation Links
U-M researchers ID promising new cancer drug
Date:3/3/2008

ANN ARBOR, Mich. Researchers have long searched for a novel cancer drug that activates a certain protein to kill tumor cells. But finding a drug that kills the cancer without causing damage to normal cells has stymied researchers.

Now, researchers at the University of Michigan Comprehensive Cancer Center have designed a small molecule that is highly effective in cell cultures at inhibiting the interaction between this protein, called p53, and another protein that inactivates p53 in cancer. The new molecule is ideal for drug development as it can be given orally as a pill and it appears to be safe for use in animals.

For more than 10 years scientists have searched for ways to block p53 inhibition, but with little success. Our study clearly shows that this can be done, says study author Shaomeng Wang, Ph.D., Warner-Lambert/Parke-Davis Professor in Medicine at the U-M Medical School and co-director of the molecular therapeutics program at the U-M Comprehensive Cancer Center.

If clinical trials prove out the drugs promise, it could have potential for treating many different types of cancer. Results of the study appear the week of March 3 in the online edition of the Proceedings of the National Academy of Sciences.

The protein p53, which normally helps suppress tumors, is inactivated in almost all human cancers. About half the time, p53 does not do its job because the gene that holds the protein is mutated or missing altogether. The other half of the time, another protein, called human MDM2, is the culprit. It binds to p53 and inhibits the tumor suppressor function of p53, promoting cancer development.

Using a computer-assisted approach, U-M researchers designed a small molecule, called MI-219, that is highly effective in blocking the interaction of MDM2 and p53. MI-219 specifically kills tumor cells by harnessing the power of p53. In animal models of human cancer, MI-219 completely inhibited tumor growth and appeared to cause no toxicity to animals.

Many traditional cancer drugs also activate p53 but they do so by causing DNA damage. They kill not only tumor cells but also normal cells, thus having severe side effects. MI-219 is unique in that it is designed to activate p53 without causing DNA damage, specifically killing tumor cells. Indeed, MI-219 is highly effective in inhibiting tumor growth, and even inducing tumor regression, but it has caused no toxicity to animals at efficacious doses, says Wang, professor of internal medicine and pharmacology at the U-M Medical School and professor of medicinal chemistry at the U-M College of Pharmacy.

In addition to its effectiveness at killing cancer cells without toxic side effects, MI-219 can be developed as a pill that patients could take orally, rather than the traditional chemotherapy drugs that must be given intravenously at a hospital or cancer center.

While promising in preclinical studies, MI-219 needs to be evaluated in human clinical trials for its safety and efficacy for cancer treatment since it is a brand new drug, Wang cautions.

"We are very excited about the therapeutic potential of MI-219 for the treatment of many types of human cancer. Ascenta is committed to advancing MI-219, which we have designated AT-219, into human clinical trials," says study author Dajun Yang, M.D., Ph.D., senior vice president of research and a co-founder of Ascenta Therapeutics, a clinical-stage biopharmaceutical company that has licensed the technology related to MI-219 from U-M and plans to aggressively advance it into human clinical trials.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. Researchers identify new genetic marker for breast cancer
2. Researchers describe mechanisms by which capon gene causes heart rhythm disturbances
3. Researchers develop new tool to predict who will use microbicides
4. USC researchers discover novel way to develop tumor vaccines
5. St. Jude Researchers Find Key Step in Programmed Cell Death
6. St. Jude researchers find key step in programmed cell death
7. Mayo Researchers Look for Explanation Behind High Incidence of Diabetes Among Asian Indians
8. Mayo researchers look for explanation behind high incidence of diabetes among Asian Indians
9. UT Southwestern researchers investigate predictors for sickle-cell-anemia complications
10. Researchers find possible target to treat deadly bloodstream infections
11. Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
U-M researchers ID promising new cancer drug
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... ... March 23, 2017 , ... March is National Kidney Month – the perfect ... comes to maintaining good health. Every day, two kidneys filter about 120 to 150 ... of your blood, eliminating waste, regulating fluid levels and blood pressure, supporting bone health ...
(Date:3/23/2017)... Scottsdale, AZ (PRWEB) , ... March 23, 2017 , ... ... helping people around the world to manage stress and anxiety. , “Buzzies change ... Serin, neuropsychologist, inventor and co-founder of Buzzies. , Since its launch date in December ...
(Date:3/23/2017)... ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and Health System ... AMN Healthcare: Susan Salka , 43rd President of the United States of America: ... My Life In and Out of the Ring: Sugar Ray Leonard , JD, ...
(Date:3/23/2017)... PA (PRWEB) , ... March 23, 2017 , ... It’s ... That means many students are thinking about summer internships , which can be ... thereof). , The pros at Garden Media Group, a boutique public relations firm outside ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017   BioSpace , ... resource, has partnered with Indiana Biosciences Research Institute ... organizations and educational institutions to bring the state,s ... first-ever BioIndiana Hotbed map, an artistic representation of the ... was presented to Vice President Mike Pence , ...
(Date:3/23/2017)... 2017  Digital Pharmacist Inc. ( ... growing digital health company, announced today that it ... patients to manage their prescriptions. Over three hundred ... Health Pharmacy, USave Pharmacy and Owen,s Healthcare use ... accelerate its product development schedule, the company now ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... ... therapy devices market to grow at a CAGR of 10.16% during ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: